AFN-1252 is a potent inhibitor of enoyl-ACP reductase fromBurkholderia pseudomallei-Crystal structure, mode of action, and biological activity
出版年份 2015 全文链接
标题
AFN-1252 is a potent inhibitor of enoyl-ACP reductase fromBurkholderia pseudomallei-Crystal structure, mode of action, and biological activity
作者
关键词
-
出版物
PROTEIN SCIENCE
Volume 24, Issue 5, Pages 832-840
出版商
Wiley
发表日期
2015-02-03
DOI
10.1002/pro.2655
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors
- (2014) Mohamed Takhi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Treatment and prophylaxis of melioidosis
- (2014) David Dance INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor
- (2014) Johannes Schiebel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Type II Fatty Acid Synthesis Is Essential for the Replication ofChlamydia trachomatis
- (2014) Jiangwei Yao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical Definitions of Melioidosis
- (2013) Allen C. Cheng et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- The Burkholderia pseudomallei Enoyl-Acyl Carrier Protein Reductase FabI1 Is Essential forIn VivoGrowth and Is the Target of a Novel Chemotherapeutic with Efficacy
- (2013) Jason E. Cummings et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects
- (2013) Nachum Kaplan et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- New drugs for methicillin-resistant Staphylococcus aureus: an update
- (2013) K. Kumar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Resistance to AFN-1252 Arises from Missense Mutations inStaphylococcus aureusEnoyl-acyl Carrier Protein Reductase (FabI)
- (2013) Jiangwei Yao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity of AFN-1252, a novel FabI inhibitor, againstStaphylococcus aureusin anin vitropharmacodynamic model simulating human pharmacokinetics
- (2013) Brian T Tsuji et al. JOURNAL OF CHEMOTHERAPY
- Mode of Action,In VitroActivity, andIn VivoEfficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor
- (2012) Nachum Kaplan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanisms of antibiotic resistance inBurkholderia pseudomallei: implications for treatment of melioidosis
- (2012) Herbert P Schweizer Future Microbiology
- From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria
- (2012) Vincent Gerusz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Melioidosis
- (2012) W. Joost Wiersinga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of Burkholderia pseudomallei in Recurrent Melioidosis
- (2012) Hillary S. Hayden et al. PLoS One
- Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection
- (2012) Sarovich et al. Infection and Drug Resistance
- Melioidosis: a clinical overview
- (2011) D. Limmathurotsakul et al. BRITISH MEDICAL BULLETIN
- Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?
- (2011) Joshua B Parsons et al. CURRENT OPINION IN MICROBIOLOGY
- Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei
- (2011) N. Liu et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors
- (2011) J. B. Parsons et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Mechanism and Inhibition of the FabV Enoyl-ACP Reductase fromBurkholderia mallei
- (2010) Hao Lu et al. BIOCHEMISTRY
- Present and future therapeutic strategies for melioidosis and glanders
- (2010) D Mark Estes et al. Expert Review of Anti-Infective Therapy
- AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
- (2009) J. A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens
- (2009) Sophie Brinster et al. NATURE
- Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
- (2008) Hao Lu et al. ACCOUNTS OF CHEMICAL RESEARCH
- Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances
- (2008) Irith Wiegand et al. Nature Protocols
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started